Dr. Shah on Updated Results With Trastuzumab Deruxtecan in DESTINY-Gastric01
Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.
Dr. Ajani on Clinical Implications of Trastuzumab Deruxtecan in Gastric and GEJ Adenocarcinoma
Jaffer A. Ajani, MD, discusses the potential clinical implications of fam-trastuzumab deruxtecan-nxki in gastric or gastroesophageal junction adenocarcinoma if approved by the FDA.
Experts Highlight Promise of Trastuzumab Deruxtecan in Gastric/GEJ Cancers
Experts share their insight on the efficacy and safety of trastuzumab deruxtecan in the gastric cancer space.
Dr. Siena on the Design of the DESTINY-CRC01 Trial in HER2+ Metastatic CRC
Salvatore Siena, MD, provides an overview of the DESTINY-CRC01 trial in DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer.
Dr. Janjigian on Updated Results from the DESTINY-Gastric01 Trial in HER2+ Gastric Cancer
Yelena Y. Janjigian, MD, discusses updated results from the phase 2 DESTINY-Gastric01 trial in previously treated patients with HER2-positive gastric cancer.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512